Nanobiotix SA License Agreement with Janssen Briefing Transcript

Jul 10, 2023 / 12:30PM GMT
Operator

Good day and thank you for standing by. Welcome to the Nanobiotix License Agreement with Janssen Pharmaceutica NV, one of Janssen Pharmaceutical Companies of J&J, for the co-development and commercialization of NBTXR3 conference call. A slide presentation accompanying this call can be found on the investor section of the company's website at www.nanobiotix.com. (Operator Instructions) Please be advised that today's conference is being recorded. At this point, I'll turn the call over to Craig West, Senior Vice President of Investor Relations of Nanobiotix.

Craig West - Nanobiotix SA - SVP, IR

Thank you, Melissa. Good afternoon and good morning, everyone, and welcome to the Nanobiotix Conference call to discuss our worldwide agreement with Janssen for the co-development and commercialization of our potentially first-in-class radioenhancer, NBTXR3. By Janssen, we mean Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of J&J. Slides for today's call can be found on the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot